Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial

Circulation. 2022 Aug 23;146(8):652-654. doi: 10.1161/CIRCULATIONAHA.121.058294. Epub 2022 Aug 22.

¹ Unit of Cardiology, Karolinska Institute & Karolinska University Hospital, Stockholm, Sweden (F.C.).
² Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (C.P.C.).
³ Pfizer Inc., Collegeville, PA (R.F.).
⁴ University of Toronto, ON, Canada (D.Z.I.C.).
⁵ University of Tennessee Health Science Center, Memphis, TN (S.D.-J.).
⁶ AdventHealth Translational Research Institute, Orlando, FL (R.E.P.).
⁷ Pfizer Inc., Groton, CT (J.P.M., S.W.).
⁸ MSD Limited, London, United Kingdom (M.M.).
⁹ Pfizer Inc., New York, NY (N.B.C.).
¹⁰ Now with Cerevel Therapeutics, Cambridge, MA (S.W.).

No abstract available

Keywords: cardiovascular diseases; diabetes mellitus, type 2; metformin; sodium-glucose transporter 2 inhibitors.

Publication types